Vanderbilt Vaccine Center

The flu mutates so quickly that we need a new vaccine every year, but Vanderbilt scientists have found a vulnerable part of the virus that doesn't mutate as much. Read More

A monoclonal antibody against the chikungunya virus developed by researchers at Vanderbilt University Medical Center is the first monoclonal antibody encoded by messenger RNA to enter a clinical trial. Read More

Using sophisticated gene sequencing and computing techniques, Vanderbilt researchers have achieved a first-of-its-kind glimpse into how the body’s immune system gears up to fight off infection. Read More

James Crowe Jr. and colleagues have developed a new computational method that may allow researchers to develop flu antibodies that can protect against more strains of the disease. Read More

Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus. Read More

Research led by James Crowe, Jr., could lead to the first effective treatment for this dangerous mosquito-transmitted infection. Read More

The discovery of these antibodies could significantly improve the diagnosis and treatment of the leading cause of stomach illness in the world. Read More

Common sequences of antibodies against HIV may be key to developing a successful vaccine strategy for the virus. Read More

A new Vanderbilt study suggests it may be possible to develop antibody therapies or a universal vaccine effective against multiple Ebola virus family members. Read More

Targeting the protein that mosquito-borne viruses use to enter cells could be a strategy for preventing infection by multiple emerging viruses. Read More

Few people die from rabid animal bites in the United States thanks to the near-universal availability of human rabies immune globulin and rabies vaccine, which are given as separate shots as soon as possible after exposure to the rabies virus. Read More

The laboratory of James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, received the 2018 Vaccine Industry Excellence Award for Best Academic Research Team at the 18th World Vaccine Congress in Washington, DC, this week. Read More

K. Dane Wittrup, PhD, a pioneer in protein engineering technologies who has helped accelerate development of antibody therapies for cancer, will deliver the next Flexner Discovery Lecture on Thursday, March 22. Read More

Newly discovered features in an RSV protein may be useful for rational structure-based vaccine design. Read More

From Vanderbilt Magazine: James Crowe, director of the Vanderbilt Vaccine Center, hopes to create a universal flu vaccine--permanently eliminating the problem of ineffective or under-effective annual flu shots. Read More

A renowned microbiologist and Ann Scott Carell Professor, Crowe is leading efforts to decipher the human immunome, a vast set of genes and molecular structures critical to fighting disease. Understanding those mechanics could lead to the development of a universal flu vaccine. No guessing required. Read More

The U.S. Defense Advanced Research Projects Agency (DARPA) has signed a five-year cooperative agreement worth up to $28 million with Vanderbilt University Medical Center (VUMC) to develop methods for preventing the global spread of viruses like chikungunya and Zika. Read More

James Crowe Jr., MD, director of the Vanderbilt Vaccine Center at Vanderbilt University Medical Center (VUMC), has been named a fellow of the National Academy of Inventors (NAI). Read More

Researchers at Vanderbilt University Medical Center are leading an international effort to develop a universal influenza vaccine that would protect everyone against all strains of the flu anywhere in the world. Read More

The Human Vaccines Project and Vanderbilt University Medical Center (VUMC) announced this week that they joined forces with Illumina Inc. to decipher the human immunome, the genetic underpinnings of the immune system. Read More